TOR-MORTEN KVAM
Positions – current and previous
| Year | Job title – Employer |
| 2007-2009 | Internship: Østfold Hospital Trust (Medical, Surgical and Psychiatric Departments) and Fredrikstad municipality (general practice) |
| 2009-2013 | Resident at Østfold Hospital, Psychiatric Department, Veum Psychiatric Hospital and Moss District Psychiatric Center |
| 2014- | Consultant psychiatrist at Østfold Hospital, Psychiatric Department, Moss District Psychiatric Center |
| 2018- | Co-founder and member of the research team PsykForsk |
| 2019-2023 | Therapist and investigator in the MP18 trial, investigating MDMA-assisted therapy for post-traumatic stress disorder |
| 2021-2025 | PhD student at the University of Oslo: “An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Therapy in Subjects with Major Depressive Disorder” |
Education
| Year | Academic degree | Institution |
| 2007 | Completed medical school with an integrated one-year voluntary research program | Norwegian University of Science and Technology |
| 2014 | Specialist in psychiatry | Østfold Hospital/The Norwegian Directorate of Health |
Grants
| Year | Funder |
| 2020 | PhD grant from South-Eastern Norway Regional Health Authority to a study of MDMA-assisted therapy for Major Depressive Disorder (project number 2021007) |
| 2024 | 24.9 million NOK to a multisite RCT investigating ketamine duration for depression (Application id 38357) |
| 2024 | 4.9 million NOK to a study of MDMA-assisted therapy for young adults with Major Depressive Disorder (project number RG24-0012) |
Other relevant assignments
| Year | Description – Role – Institution |
| 2021- | Member of the Psychedelic Group at Department of Psychology, University of Oslo |
| 2023- | Member of the Norwegian network for rapid-acting antidepressants (NORAAD) |
| 2015 | Approved as a cognitive behaviour therapy (CBT) therapist, after completing education over two years, Norwegian Association for Cognitive Behavioural Therapy |
| 2018 | Investigator and therapist training for the Compass Pathways psilocybin for treatment resistant depression trial, Lisbon, Portugal. |
| 2019 | Therapist training for the MAPS MDMA-assisted psychotherapy for PTSD trial, Asheville, North Carolina, USA. |
| 2021 | Certificate of completion, MDMA-Assisted Therapy (100 Hours of Training plus Supervision) |
| 2021 | Involved in the start-up of IV ketamine for treatment-resistant depression in the first outpatient clinic in Norway |